Impact of HIV and antiretroviral drug exposure on lung growth and function over 2 years in an African Birth Cohort.
To assess the impact of HIV and antiretroviral (ARV) exposure without infection on lung growth and function over the first 2 years of life. Prospective observational study of an African birth cohort, Drakenstein Child Health Study (DCHS). Infants enrolled antenatally had lung function measured at 6 weeks, 1 and 2 years. HIV-infected women received ARV therapy (ART) as per local guidelines. The association between HIV and ARV exposure with lung function was assessed using mixed effects modelling. Of 1143 infants born, 2 HIV-infected infants were excluded from analysis; 909 (80%) infants had lung function collected at 6 weeks (190 [21%] were HIV-exposed uninfected [HEU]); 782 (69%) at 1 year and 741 (65%) at 2 years. At 6 weeks HEU infants had larger tidal volume (TV) compared to HIV unexposed infants (1.13 mL, CI: 0.02 to 2.23, p = 0.045). High maternal viral load was associated with a 17% lower expiratory flow over 2 years (0.17, CI 0.00 to 0.34, p = 0.046). First-line ART initiated during pregnancy was associated with lower infant TV at 6 weeks compared to those who initiated ART before pregnancy (-2.7 mL, -5.31 to -0.10, p = 0.042), and low maternal CD4 cell counts associated with lower infant tidal over 2 years (-11.1 mL, -18.58 to 3.58, p = 0.004). HIV exposure is associated with altered lung function in early life, with a vulnerable HEU subgroup based on maternal disease severity, immunological compromise and ART exposure. This data highlights the importance of ongoing surveillance of respiratory health in HEU children.